Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients.

Next Previous
Trial Profile

Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lactoferrin 1-11 (Primary)
  • Indications Bacterial infections; Mycoses
  • Focus Adverse reactions
  • Sponsors AM-Pharma

Most Recent Events

  • 12 Jan 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 14 Apr 2009 New source identified and integrated (Netherlands Trial Register NTR672).
  • 16 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Jun 2009, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top